Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S posts an AlphaScore of 55/100 in the healthcare sector. Key metrics as of October 11, 2026, include a return on equity of 118.78% and a net margin of -31.67%. A major strength is its stellar revenue growth of 98.03%, reflecting explosive top-line gains. A primary risk is its negative net margin of -31.67%, indicating ongoing unprofitability relative to sales.

Written 11/10/2026, 00:40:23 UTC · Snapshot 11/10/2026